Steve R. Bailey
@Frazier Life Sciences Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.
Assets under management
The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RAREUltragenyx Pharmaceutical In
| 1.42% | $35.203M 633,715 shares@ $55.55 avg price | Increased 49.11% |
SVRASavara Inc
| 1.39% | $34.587M 8.157M shares@ $4.24 avg price | |
CGONCg Oncology Inc
| 1.17% | $29.052M 770,000 shares@ $37.73 avg price | |
RCKTRocket Pharmaceuticals Inc
| 1.1% | $27.44M 1.486M shares@ $18.47 avg price | Decreased -4.84% |
TRVITrevi Therapeutics Inc
| 0.99% | $24.653M 7.381M shares@ $3.35 avg price | |
MREOMereo Biopharma Group Plc
| 0.84% | $20.952M 5.098M shares@ $4.12 avg price | Increased 15.83% |
SLNSilence Therapeutics Plc
| 0.84% | $20.881M 1.149M shares@ $18.18 avg price | |
ASNDAscendis Pharma A S
| 0.8% | $19.908M 133,333 shares@ $149.31 avg price | New Position |
HLVXHillevax Inc
| 0.75% | $18.686M 10.617M shares@ $1.76 avg price | |
MRUSMerus N V
| 0.75% | $18.64M 373,100 shares@ $49.96 avg price |